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List of abbreviations 
 
ANT1 / ANT2 adenine nucleotide translocase 1 / 2 
AT adipose tissue 
% body fat percentage of body fat 
°C degree celcius 
µg microgram 
µkat microkatal 
µl microliter 
µmol micromol 
adi  adipocyte 
adj. adjusted 
ALAT alanine aminotransferase 
ASAT aspartate aminotransferase 
AU arbitrary unit 
bHLH basal Helix-loop-helix domain 
BMI body mass index 
CBP calcium response element binding protein 
cDNA complementary DNA 
c/EBPα CCAAT/enhancer binding protein α 
cm centimetre 
CpG cytosine-phosphate-guanine dinucleotide 
CRP C-reactive protein 
CT computed tomography 
CT ratio visceral fat area / subcutaneous fat area 
C-TAD C-terminal transactivation domain 
DNA desoxyribonucleic acid 
dl deciliter 
DNMT DNA methyltransferase 
dNTP deoxyribose nucleoside triphosphate 
ENCODE encyclopedia of DNA elements 
EWAS epigenome-wide association studies 
FAM 6-Carboxy-Fluorescein 
FD fat distribution 
FFA free fatty acid 
FIH factor inhibiting HIF 
FPG fasting plasma glucose 
FPI fasting plasma insulin 
fT3 free triiodthyronine 
  
fT4 free tetraiodothyronine 
g gram 
GEO gene expression omnibus 
gGT gamma-glutamyl transferase 
GIR glucose infusion rate 
HbA1c glycohemoglobin 
HDL-C high density lipoprotein cholesterol 
HFD high fat diet 
HIF1α / HIF2α / HIF3α/ 
HIFβ 
Hypoxia-Inducible Factor 1α / 2α / 3α / β  
HIF-p4H HIF prolyl 4-hydroxylase 
HPRT1 hypoxanthine guanine phosphoribosyltransferase 1 
HRE hypoxia responsive element 
IL-1b / IL-6b interleukin 1b / 6b 
kg kilogram 
l liter 
LDL-C low density lipoprotein cholesterol 
ln natural logarithm 
LXXLL peptide recognition motif 'Leu-Xaa-Xaa-Leu-Leu' 
LZIP leucine zipper 
m metre 
MAF minor allele frequency 
Met methylation 
mg  milligram 
MgCl magnesium chloride 
min minunte 
Mio million 
miRNA microRNA 
ml  milliliter 
mmol  millimole  
MRI magnetic resonance imaging 
mRNA messengerRNA 
mU/l microunits per milliliter 
ng  nanogram 
NGT normal glucose tolerance 
nl nanoliter 
N-TAD N-terminal transactivation domain 
O2 oxygen 
ODD oxygen-dependent degradation domain 
oGTT oral glucose tolerance test 
p300 E1A binding protein p300 
p53 tumor protein p53 
PAS domain Per-Arndt-Sim domain 
pg  picogram 
pmol picomole 
  
pO2 partial pressure of oxygen 
PPAR Peroxisome proliferator-activated receptor 
Pro proline 
r correlation coefficient 
RNA ribonucleic acid 
RT-PCR reverse transcription polymerase chain reaction 
s second 
SAT subcutaneous adipose tissue 
sc subcutaneous 
SD standard deviation 
SEM standard error of the mean 
SFA saturated fatty acids 
SNP single nucleotide polymorphism 
SVF stromal vascular fraction 
T2D type 2 diabetes 
TG triglycerides 
TNFα Tumor necrosis factor α 
TSH thyroid-stimulating hormone 
VAT visceral adipose tissue 
VHL Von-Hippel-Lindau tumor supressor protein 
vis visceral 
vs. versus 
WHO World Health Organisation 
WHR waist-to-hip ratio 
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1 Introduction 
1.1 Obesity and its associated pathomechanisms 
1.1.1 Obesity: a global health burden 
Obesity constitutes an emerging global health problem. Worldwide 38% of adults aged 18 
and over were overweight in 2014 (BMI 25-29,9kg/m²; 38% of men and 40% of women) 
and 13% were obese (BMI greater than or equal to 30kg/m²; 11% of men and 15% of women) 
(WHO). Obesity has more than doubled since 1980 (WHO). Figure 1 shows the world-wide 
prevalence of overweight by country in 2014. 
 
Figure 1. Prevalence in % of overweight in adults 18 years and older by country in 2014  
(http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/overweight/flash/atlas.html).  
Source: WHO.  
Overweight and obesity used to be considered high-income country problems. However, 
they now depict a growing problem also in low- and middle-income countries, where the 
rate of increase of childhood overweight and obesity has recently been more than 30% higher 
than that of developed countries (WHO, 2014). Overweight and obesity are defined as 
abnormal or excessive fat accumulation that may impair health (WHO). The Body-Mass-
Index (BMI) is a commonly used measure to quantitate obesity.  It is defined as a person’s 
weight in kilograms divided by the square of his height in meters (kg/m2). According to the 
WHO definition, a BMI greater than or equal 25 is overweight and a BMI greater than or 
equal 30 is obese. Factors determining BMI are mostly energy metabolism, nutrition and 
exercise, environmental factors and genetic factors (1).  
 8 
 
 Obesity significantly increases the risk of developing type 2 diabetes, hypertension, 
coronary heart disease, stroke, fatty liver disease, dementia, obstructive sleep apnea and 
some types of cancer (2–9). Globally, 44% of diabetes, 23% of ischemic heart disease and 
7–41% of certain cancers are attributable to overweight and obesity (WHO, 2014). However, 
obesity itself is not alone relatable to these secondary diseases (10–13). Particular 
distinctions in body composition, fat distribution and adipose tissue function are considered 
to be more relevant for the development of obesity-associated disorders (14, 10, 11, 15), as 
individuals with low subcutaneous but increased visceral fat mass suffer an increased 
cardiometabolic risk (16, 17, 15, 13). 
1.1.2 Adipose tissue 
Adipose tissue is composed of different cells, connective tissue matrix, vascular and neural 
tissues (18). The cell population of adipose tissue consists of adipocytes and of a cell 
population called the stromal vascular fraction which includes monocytes, macrophages, 
pericytes, endothelial precursor cells, pre-adipocytes and adipocytes-derived mesenchymal 
stem cells (19). Adipocytes constitute the main cell population of adipose tissue. Free fatty 
acids and glycerol are stored in adipocytes as triglycerides (18). In periods of starvation these 
triglycerides can be mobilized for lipolysis and β-oxidation, thus serving as an energy 
storage system (18). Excess energy intake with limited energy expenditure conditions the 
accumulation of adipose tissue (18). In addition to the storage and release of lipids, adipose 
tissue secretes bioactive factors, adipokines, which have various functions concerning 
adipose tissue (e.g. regulating adipogenesis, immune cell migration in adipose tissue and 
adipocyte metabolisms) and the whole body (e.g. affection of the immune response, 
inflammation, glucose metabolism, insulin sensitivity and blood pressure) (14, 20, 21). 
Leptin, one of the most well studied adipokines, plays an important role in the regulation of 
satiety, appetite and energy expenditure (22). It lowers appetite in response to food intake 
by influencing signaling in the hypothalamus (22). 
Adipose tissue develops from pluripotent mesenchymal stem cells which differentiate to 
preadipocytes and later to adipocytes (23). Key players involved in adipogenesis are the 
nuclear hormone receptor PPARG and CCAAT/enhancer binding protein α (C/EBPα).  
C/EBPα is a transcription factor that regulates PPARG (24). PPARG regulates 
transcriptional gene activation and is an essential regulator of adipocyte differentiation and 
lipid storage in AT (25).  
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About 80% of all body fat is located subcutaneously (SAT), mainly in the femorogluteal 
regions, back and anterior abdominal wall (18, 26). 10-20% of body fat in men and 5-8% in 
women are located in visceral depots (VAT) (18, 26). VAT is considered ectopic storage of 
adipose tissue and is mainly to be found in the central torso area surrounding organs. Ectopic 
fat storage further includes omental, pericardial, perirenal, and retroperitoneal fat deposition. 
Intraabdominal visceral accumulation of fat is associated with a much greater risk for the 
development of obesity associated comorbidities than subcutaneous fat accumulation (11, 
15, 13). VAT and SAT differ biologically as VAT displays decreased insulin sensitivity, 
lower angiogenic potential, increased lipolytic activity, a different cellular composition and 
a different expression pattern of genes regulating adipocyte function (26). Whereas VAT is 
more vascular, innervated and contains a higher number of inflammatory and immune cells, 
SAT has a higher preadipocyte differentiating capacity and a lower percentage of large 
adipocytes (18).VAT drains into the portal vein, exposing the liver to FFA and adipokines 
released from adipocytes (14, 18). Adipokines activate hepatic immune mechanisms and 
stimulate the production of inflammatory mediators (27, 28). All of this could contribute to 
the deleterious consequences of visceral obesity, playing important roles in the development 
of obesity-associated metabolic and cardiovascular diseases.  
The distribution of adipose tissue depends on various factors, like genetics, age, gender, total 
body fat content and energy balance (26). In young females, the subcutaneous abdominal fat 
area tends to be dominant over the abdominal visceral fat area. At the age of about 60, 
postmenopausal, this fat distribution shifts towards the predominantly visceral fat 
accumulation commonly found in men (29), due to the effect of sex hormones on fat 
distribution (30). The amount of visceral fat increases with age in both genders (29). A 
positive energy balance has only negligible impact on visceral fat accumulation. Hyper-
energetic nutrition in monozygotic twins was associated with an increase in subcutaneous 
fat mass, whereas the variation in visceral fat did not exceed 10% (31). In contrast, body 
weight loss results in an over-proportional reduction of the visceral fat mass, probably due 
to the higher lipolytic activity of visceral compared with subcutaneous adipose tissue (32, 
26). 
1.1.3 Development of hypoxia in adipose tissue 
Hypoxia is commonly found in obese adipose tissue. Several mechanisms are suspected to 
contribute to the development of hypoxia in obese adipose tissue (33). First, despite the 
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expansion of adipose tissue and total body fat mass in obesity, the proportion of the cardiac 
output and the dimension of blood flow to adipose tissue does not show an increase (34, 35). 
Second, whereas lean subjects show a postprandial increase in blood flow to adipose tissue, 
this rise cannot be observed in obese patients (36, 37). Third, the obesity-associated 
enlargement of adipocytes which can be up to 150-200µm in obese (38) can surmount the 
diffusion distance of oxygen of 100-200µm (39). Further, it has been shown that capillary 
density is lower in AT of obese individuals than in lean individuals (40, 41). Adipocyte 
hypertrophy results in adipose tissue expansion and, expanding the angiogenic potential, can 
be accompanied by insufficient vascularization (40).  This results in increased distances 
between single adipocytes and capillaries, forming areas of adipose tissue with decreased 
blood perfusion and conditions the development of areas of adipose tissue hypoxia (40). 
Hypoxia in adipose tissue could be verified through direct measurement of oxygen tension 
in adipose depots of obese mice with fiber-optic O2 sensors (42, 43). A pO2 of 48mmHg was 
measured in AT of lean mice, whereas for obese mice, the pO2 was 15.2mmHg, providing 
direct evidence of hypoxia in obese adipose tissue in rodents (43). In humans, relative 
hypoxia in adipose tissue in obesity could be confirmed through a study showing that the 
pO2 in subcutaneous AT of the upper arm is ~20mmHg lower in obese than in lean subjects 
(35). 
1.1.4 Inflammation in adipose tissue 
Adipose tissue expanison is closely related to chronic inflammation in adipose tissue, liver 
and skeletal muscle (44, 45, 33, 43). Chronic inflammation in adipose tissue gradually leads 
to the establishment of secondary pathological reactions such as insulin resistance, 
hyperinsulinemia and glucose intolerance (46). The relationship between obesity and 
inflammation was discovered with the observation that TNFα was elevated in obese adipose 
tissue and that inhibition of this cytokine improved glucose tolerance and insulin sensitivity 
(47). Further studies revealed that a key mechanism contributing to the establishment of 
obesity-induced inflammation is the accumulation of increased numbers of tissue 
macrophages (48, 49). These adipose tissue macrophages secrete different proinflammatory 
cytokines, like TNFα, IL1b and IL6, which can directly inhibit insulin action in insulin target 
cells (i.e. hepatocytes, myocytes, adipocytes) (50, 51) or leak into the systemic circulation 
and cause insulin resistance through endocrine effects, further contributing to the 
establishment of an inflammatory state. 
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It is suggested that adipose tissue hypoxia triggers the inflammatory process (42, 43). 
However, the early events that initiate the cascade remain to be poorly understood. Part of 
this inflammation process is triggered by HIF1α, a hypoxia inducible transcription factor 
that shows increased expression levels early in response to high fat diet fed mice (52). The 
state of relative adipocyte hypoxia provides the stimulus for HIF1α induction (53, 54). 
HIF1α can play a key initiating role in adipose tissue macrophage accumulation and 
inflammation by stimulating the production of adipocyte-derived chemokines and attracting 
macrophages (55, 52), thereby contributing to the establishment of an inflammatory state. 
1.2 The transcription factor family of “hypoxia 
inducible factor” 
1.2.1 The function of hypoxia inducible factors 
Hypoxia-inducible factors are transcription factors that largely mediate hypoxia response 
(53). They are heterodimeric transcription factors consisting of an oxygen-labile α-subunit 
and a constitutively expressed β-subunit. Upon binding to specific sequences named hypoxia 
responsive elements (HREs) in their target genes, they mediate transcription of a large 
number of genes whose products are involved in erythropoiesis, angiogenesis, metabolic 
reprogramming, cell-cycle-regulation, and tumor progression (56, 57). Three different 
isoforms of the α-subunit, HIF1α, HIF2α and HIF3α, exist and allow the formation of 
transcription factors with different functions upon dimerizing with HIFβ. HIF1α and HIF2α 
are the most structurally similar, containing a basal Helix-loop-helix (bHLH) domain, two 
PAS domains, an oxygen-dependent-degradation domain (ODD), an N-terminal 
transactivation domain (N-TAD), and a C-TAD, of which the N-TAD partially overlaps with 
the ODD (58, 59). In normoxia, they are hydroxylated in at least one of the two critical 
prolines in their ODD, Pro402 or Pro564, allowing the E3 ubiquitin ligase von-Hippel-
Lindau-Protein to ubiquitinate a leucine-residue, thereby marking them for proteasomal 
degradation (60, 61). In humans, this hydroxylation is catalyzed by three oxygen dependent 
HIF prolyl 4-hydroxylases (HIF-P4Hs 1-3) (62–65). Furthermore, the hydroxylase factor 
inhibiting HIF (FIH) hydroxylates an asparagine in the C-terminal transactivation domain 
(C-TAD) of HIF1α and HIF2α, preventing the binding of coactivator creb binding protein 
CBP/p300 and thereby inhibiting the full transcriptional activity of HIF1α and HIF2α in 
normoxia (66–68). In hypoxia, HIF-P4Hs and FIH are inhibited, resulting in reduced 
hydroxylation of the ODD and the CTAD, which prohibits degradation of HIF1α and HIF2α. 
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The stabilized HIFα -subunit is able to dimerize with the HIFβ subunit, allowing the complex 
to bind to the hypoxia-responsive elements in the promoter region of its target genes (69, 
70). These HIF1α and HIF2α target genes allow regulation of various biological processes 
such as erythropoiesis, angiogenesis, metabolic reprogramming, cell-cycle-regulation, and 
tumor progression, displaying master regulators of the transcriptional response to hypoxia 
(56, 57). A schematic presentation of HIF regulation under normoxic and hypoxic conditions 
is shown in Fig.2. 
 
Figure 2. HIF regulation under normoxic and hypoxic conditions. Under normoxic conditions, HIFα is 
hydroxylated and ubiquitinated and thereby marked for proteasomal degradation. Under hypoxic conditions, 
HIFα is stabilized and forms a complex with HIFβ and p300 that is capable of activating transcription of target 
genes. VHL = von-Hippel-Lindau-Protein, HRE = hypoxia responsive elements, Ub = ubiquitin, OH = 
hydroxyl group, Pro = proline, Asn = asparagin. (own graphic) 
1.2.2 The role of hypoxia inducible factor 3α 
HIF3α structurally differs from HIF1α/2α, possessing a leucine zipper domain (LZIP) as 
well as an LXXLL motif (71). HIF3α lacks the CTAD, and thus cannot bind CBP/p300 (71, 
72). The HIF3α ODD differs from those of HIF1α and HIF2α as it contains only one 
hydroxylatable proline corresponding to Pro564 in HIF1α, being oxygen-dependently 
regulated through hydroxylation by the HIF-P4Hs (64, 73). The function of HIF3α differs 
from that of HIF1α/2α, displaying various roles in different biological processes. Multiple 
isoforms of HIF3α exist, HIF3A being subject to extensive alternative splicing and different 
promoter- and transcription start site utilization (72, 74, 75). The existence of the variants 
HIF3α-1, HIF3α-2, HIF3α-4, HIF3α-7, HIF3α-8, HIF3α-9 and HIF3α-10 could be 
 13 
 
confirmed in various human tissues (76). A schematic representation of HIF1α, HIF2α and 
the HIF3α isoforms is shown in figure 3.  
 
Figure 3. Schematic presentation of HIF1α, HIF2α and the HIF3α variant proteins. bHLH = basic helix-
loop-helix, PAS = Per/Arndt/Sim, ODD = oxygen-dependent degradation domain, NTAD and CTAD = N- and 
C-terminal transactivation domain, LZIP = leucine zipper, P = prolines hydroxylated in the ODD, aa = amino 
acids (own graphic modified from (77)) .   
Some of these HIF3α isoforms show weak or no transcriptional activity upon testing in vitro 
in human/mammalian cells and some of these isoforms even lack any TAD (71, 72, 76). The 
splice variant HIF3α-4 was even able to suppress HIF1α and HIF2α-induced reporter 
construct expression in cultured cells in overexpression experiments (73). Overexpression 
of all the HIF3A variants in cell cultures was shown to inhibit the transcriptional activation 
of an HRE-reporter by HIF1α and HIF2α (77). These studies led to the conclusion that HIF3α 
functions as a negative regulator of HIF1α and HIF2α. However, this view is derived from 
overexpression experiments performed in cell culture systems that may differ from the 
functioning of the endogenous protein in vivo. Recent studies reported that HIF3α functions 
as a transcriptional activator in the hypoxia response in zebrafish embryos (78). According 
to this study, HIF3α is capable of activating certain target genes independent or in 
collaboration with HIF1α, suggesting a role of HIF3α in glucose and amino acid metabolism, 
apoptosis, proteolysis, p53 signaling and PPAR signaling. HIF3α has further been shown to 
be involved in adipocyte differentiation, as it was found to be induced during 3T3-L1 
adipocyte differentiation and to be expressed in the differentiated adipocytes (79). Ectopic 
expression of HIF3A was shown to induce the expression of several genes related to 
adipocytes and to enhance adipogenic potential, suggesting HIF3α to function as an 
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accelerator of adipogenesis (79). HIF3α was further shown to be induced by insulin and 2-
deoxy-glucose in rats, suggesting the transcriptional up-regulation of HIF3A to constitute a 
typical response to hypoglycaemia and glucoprivation in vivo (79, 80). Collectively, these 
studies suggest HIF3α to be involved in metabolic derangements and in mechanisms 
resulting in the establishment of acquired obesity. 
1.3  Genetics and epigenetics 
1.3.1 Epigenetic mechanisms 
Epigenetics is defined as an alteration in genomic signaling caused by modifications of 
chromosomes without affecting the genomic DNA sequence (81). This is achieved through 
chemical modification of the DNA region itself or through modifications of proteins that are 
closely associated with the locus (82). The specific targeting of genetic loci ensures a local 
effect of the alteration (82). Mechanisms allowing these alterations are histone modification 
(83, 84), DNA methylation (85), and long noncoding RNAs (86). Together, these 
mechanisms influence gene expression by adapting regions of the genome to achieve gene 
silencing or activation. Histone modification and DNA methylation interfere with the 
confirmation of chromatin, which influences the gene activity by altering the DNA 
accessibility to the transcription machinery (82). Figure 4 shows the most well investigated 
epigenetic mechanisms: DNA methylation and post-translational modifications of histone 
proteins such as acetylation, methylation, ubiquitination or phosphorylation. 
 
Figure 4. Epigenetic mechanisms affecting the regulation of gene expression. Methylation of cytosine 
residues (C) within the DNA and modification of lysine (K) and arginine (R) residues of histone proteins. Me 
= methyl group, Ac = acetyl group, P = phosphor, Ub = ubiquitin. Source: 
http://www.promega.de/resources/product-guides-and-selectors/protocols-and-applications-guide/epigenetics 
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1.3.2 The methylation of DNA 
DNA methylation is the predominant epigenetic modification in vertebrates (87). A methyl 
group from S-adenosine methionine is attached to the 5’ position of a cytosine residue within 
a cytosine-phosphate-guanine (CpG) dinucleotide, creating 5-methylcytosine. The DNA 
methyltransferases DNMT3a, DNMT3b and DNMT3l catalyze de novo methylation, 
whereas DNMT1 is able to maintain methylation during DNA replication by recognizing 
hemimethylated CpGs and copying the DNA methylation pattern from the parental to the 
newly synthesized DNA strand (88, 89). This allows the patterns of DNA methylation to be 
relatively stable and to be maintained through cell generations. In addition to this, active and 
passive demethylation of DNA can allow dynamic regulation of gene expression (90). CpG 
dinucleotides are often located in short (approximately 1 kb) CpG-rich regions known as 
CpG-islands, which can be found in more than 50% of the genes in vertebrate genomes (91) 
and are often located within or close to the promoter region of genes. Methylation of CpG 
islands in proximity to the promotor results in repressed gene expression as the methylated 
DNA becomes inaccessible for the transcription machinery (92, 91). Furthermore, long-term 
silencing of genes such as imprinted genes, or tissue-specific genes in tissues where the gene 
is not expressed can be mediated via methylation of transcription start sites (91). Low 
methylation levels at the transcription start sites are, in contrast, associated with 
transcriptionally active genes. Contrary to this, DNA methylation in the gene body seems to 
be beneficial for transcription elongation (91). Thus, the effect of DNA methylation may not 
be causal, but have different functions depending on the context. DNA methylation is further 
involved in transcriptional regulation of genes and  miRNA, control of alternative promoter 
usage, and alternative splicing (93–95). DNA transcription and phenotypic variation can be 
influenced by methylation. However, the determinants of DNA methylation itself remain 
poorly understood. 
1.3.3 Epigenetics in association with obesity 
Obesity is a multifactorial disease caused by an interaction of effects of genetics, epigenetics 
and the environment (96). Environmental factors depict dietary and physical activity 
patterns. More than 40 genetic variants are known to contribute to the etiology of obesity 
and more than 30 SNPs are associated with variations in BMI (97, 98). However, genetic 
variants identified so far are not sufficient in explaining the heritability of obesity. Therefore, 
epigenetic modifications, which affect long-term gene expression need to be acknowledged 
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as possible factors influencing the BMI (99). DNA methylation can be affected by both 
genetic and environmental factors (100, 101). It is plausible that an epigenetic change caused 
by integrating these factors results in an altered downstream functional outcome, influencing 
the phenotype (102). This might possibly play a role in the pathophysiology of obesity and 
adverse fat distribution. Previous studies confirmed functionally relevant methylation 
differences between different adipose depots in pigs, supporting the role of epigenetics in 
the regulation of fat distribution (103). Genome-wide analyses of methylation at CpG sites 
in relation to BMI revealed different sites in HIF3A to show an association between 
methylation and BMI in whole blood and in adipose tissue (104–106).   
1.3.4 Single nucleotide polymorphisms in obesity 
Single nucleotide polymorphisms (SNPs) are variations at specific locations in the genome. 
These variations consist of sequence differences in single nucleotide positions (107). In 
every 1000 bases along the human chromosomes, approximately one nucleotide position 
differs between any two copies of that chromosome (108, 109). The locus is regarded as 
polymorphic when it exists in two or more variants and the allele frequency of the most 
common variant is <90% (110). Some of these SNPs directly affect protein structure or 
expression levels of genes. Therefore, they directly influence the transcriptome, and can, if 
they are located in relevant sites, represent genetic mechanisms in the etiology of various 
diseases. To date, more than 30 SNPs are known to be associated with BMI, which together 
explain about 1.5% of interindividual variation in BMI (98). DNA sequence variation can 
further influence DNA methylation levels (111, 112). Two SNPs have been shown to be 
associated with methylation at the sites mentioned above. However, they did not show an 
association with BMI (105). 
1.4 Main hypothesis 
Here we tested the hypothesis that HIF3A mRNA expression and CpG-sites methylation in 
AT is related to parameters of adipose tissue distribution and function. In paired samples of 
subcutaneous AT (SAT) and visceral AT (VAT) from 603 individuals with a wide range of 
age, BMI and obesity-related parameters, we investigated whether HIF3A mRNA expression 
is fat depot-specific, altered in obesity and related to measures of AT function and insulin 
sensitivity. In a subgroup of 548 individuals, we investigated the effects on HIF3A genetic 
variants on HIF3A AT expression and HIF3A methylation of CpG-sites.  
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1.5 Aim of this study 
The aim of our study is to further investigate the relation between hypoxia inducible factors 
and obesity. We thereby aim to contribute to a better understanding of the pathophysiological 
mechanisms involved in obesity. Genome-wide analysis of methylation at CpG sites in 
relation to BMI revealed several sites of HIF3A to show an association between methylation 
and BMI in whole blood and in adipose tissue (104–106). Two SNPs have been shown to be 
associated with methylation at these sites, but to be independent of BMI (105). Downstream 
effects of obesity-induced epigenetic changes resulting in modified signaling of the HIF-
system could mediate important mechanisms in answer to energetic dysbalance. It is 
therefore of great importance to further investigate the coherence between hypoxia inducible 
factors and development of obesity-associated comorbidities, possibly revealing important 
insights into pathophysiological processes concerning AT-inflammation, insulin resistance 
or the etiology of obesity. We therefore tested the hypothesis that expression of HIF3A in 
human subcutaneous and visceral AT is related to BMI, parameters of fat distribution and 
AT function, metabolic traits, genetic variation and methylation of CpG-sites in HIF3A.  
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higher in SAT compared to VAT and correlated with obesity and parameters of AT dysfunction (including 
CRP and leucocytes count). 	͹͸͸;ͿͷͶͽͶƤ
ǡǤ;ͷͶ͸ͻͿͻƤ
association with AT 	͹ methylation levels as well as with obesity and fat distribution. 	͹ 
ƤǡǤ
data support the hypothesis that HIF pathways may play an important role in the development of AT 
dysfunction in obesity.
Obesity and its associated comorbidities constitute an evolving health burden worldwide1. Obesity is closely 
related to chronic inammation in adipose tissue, liver and skeletal muscle2, which may contribute to chronic 
systemic inammation, insulin resistance, and deterioration in glucose and lipid metabolism3. Upon weight gain, 
adipocyte hypertrophy may lead to hypoxia in adipose tissue which is considered as a causative factor in adipose 
tissue dysfunction4–7. It has been recently shown that adipose tissue expression of hypoxia inducible factor (HIF) 
1A (HIF1A) increases in mice exposed to high fat diet4. In states of relative adipose tissue hypoxia, induction of 
HIF1α 5,6 stimulates accumulation of macrophages in adipose tissue4,7 and the production of adipocyte-derived 
pro-inammatory cytokines. HIFs are heterodimeric transcription factors that mediate hypoxia response in var-
ious tissues6. !ey consist of an oxygen-labile α -subunit and a constitutively expressed β -subunit. !ree existing 
isoforms of the α -subunit, HIF1α , HIF2α and HIF3α , allow the formation of transcription factors with di"erent 
functions upon dimerizing with HIFβ . Multiple isoforms of HIF3α exist8. HIF3α is capable of activating certain 
target genes independent or in collaboration with HIF1α , suggesting a role of HIF3α in glucose and amino acid 
metabolism, apoptosis, proteolysis, p53 signaling and PPAR signaling. In addition, HIF3α has been shown to play 
a role in adipocyte di"erentiation9,10.
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Recent genome-wide analysis of DNA methylation in whole blood and human adipose tissue revealed an asso-
ciation of methylation at three CpG sites in intron 1 of HIF3A with BMI11–13. In addition, two single nucleotide 
polymorphisms (SNPs) rs8102595 and rs3826795, have been shown to be associated with methylation at these 
sites, yet to be independent of BMI11. !e strong relationship of HIF3A methylation and obesity was also shown in 
neonates14. Furthermore, gene-diet interactions between the methylation-associated SNP rs3826795 and vitamin 
B intake were recently reported, providing a potential causal link between the epigenetic status and obesity15.
Further investigation of the relationship between HIFs and development of obesity-associated comorbidities 
might reveal important insights in pathophysiological processes concerning AT in"ammation and/or insulin 
resistance in the etiology of obesity related metabolic diseases. We therefore tested the hypothesis that expression 
of HIF3A in human subcutaneous and visceral adipose tissue is related to obesity, parameters of fat distribution 
and adipose tissue function. We further assessed the relationship between the AT expression, genetic variation 
(rs8102595 and rs3826795) and methylation of CpG-sites in HIF3A.
Material and Methods
Study participants. A total of 288 Caucasian men and 577 women were included in the study (Table 1). 
According to the ADA criteria, 343 subject were diagnosed with type 2 diabetes (T2D) and 484 had normal glu-
cose tolerance (NGT)16. Paired samples of visceral adipose tissue and subcutaneous adipose tissue were obtained 
from 603 individuals following open abdominal surgery for gastric banding, cholecystectomy, weight reduction 
surgery, abdominal injuries or explorative laparotomy. Patients with end-stage malignant diseases were excluded 
from the study. All adipose tissue samples were frozen immediately in liquid nitrogen a$er explantation and 
stored at − 80 °C. Six-hundred and three subjects (mean age 50 ± 14 years, mean BMI 43.6 ± 13.0 kg/m2) were 
included into adipose tissue HIF3A mRNA expression analysis. DNA methylation analysis was performed in 
a subgroup of 87 subjects (mean age 58 ± 15 years, mean BMI 32.9 ± 12.7 kg/m2). Genotyping was done in 548 
individuals overlapping with adipose tissue biopsy donors (mean age 50 ± 14 years, mean BMI 34.6 ± 13.6 kg/m2).
Phenotypic characterization including anthropometric measurements, body fat analysis (bioimpedance anal-
yses or dual-energy X-ray absorptiometry) and metabolic parameters such as fasting plasma glucose and insulin, 
a 75-g oral glucose tolerance test (oGTT), HbA1c, lipoprotein-, triglyceride-, free fatty acid- and adipokine serum 
concentrations was performed as previously described17,18. Measurement of abdominal visceral and subcuta-
neous fat areas (N = 245) was performed using computed tomography (CT) or MRI scans. All subjects had a 
stable weight, de&ned as the absence of "uctuations of > 2% of body weight for at least 3 months before surgery. 
In addition, adipocytes and cells of the stromal vascular fraction were isolated from adipose tissue samples of 35 
subjects (18 men, 17 women). Adipocytes were isolated by collagenase (1 mg/ml) digestion. To determine cell size 
distribution and adipocyte number, aliquots of adipocytes were &xed with osmic acid and counted in a Coulter 
counter as previously described19. !e study was approved by the ethics committee of the University of Leipzig 
(approval number: 159-12-21052012) and all subjects gave written informed consent. All methods were carried 
out in accordance with the approved guidelines.
Analysis of human 	͹ mRNA expression. Brie"y, human HIF3A mRNA expression was measured 
by qRT-PCR using TaqMan Gene Expression Assay (Applied Biosystems, Darmstadt, Germany). Total RNA was 
isolated from adipose tissue samples using the Qiacube System (Qiagen, Hilden, Germany), and 2 µ g RNA were 
reverse transcribed with standard reagents (Life Technologies). Further details including PCR conditions are 
provided in the Supplemental material. !e following Gene Expression Assay was used: Hs00541709_M1 (tag-
ging the transcripts NM_022462.4, NM_152794.3, NM_152795.3, NM_152796.4). HIF3A mRNA expression 
was calculated relative to the mRNA expression of hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1), 
determined by the assay Hs01003267_M1 (Applied Biosystems, Darmstadt, Germany). Expression of HIF3A 
and HPRT1 mRNA were quanti&ed by using the second derivative maximum method of the TaqMan So$ware 
(Applied Biosystems).
For expression analysis of HIF3A in adipocytes and stromal vascular fraction, total RNA was isolated from 
adipocytes and stromal vascular fraction extracted from 35 paired samples of subcutaneous and visceral adipose 
tissue. 300 ng RNA were reverse transcribed with standard reagents and from each RT-PCR, 23.5 µ l was ampli&ed 
in a 40 µ l PCR using the Taqman Gene Expression Assay and the TaqMan Fast Advanced Mastermix according 
to the manufacturer’s instruction. HIF3A mRNA expression was calculated relative to the mRNA expression 
of HPRT1 mRNA or 18S rRNA, determined by the assay Hs01003267_m1 (Applied Biosystems, Darmstadt, 
Germany).
ƤǤ Brie"y, genomic DNA was extracted using the DNeasy Blood 
and Tissue Kit (Qiagen, Hilden, Germany) and bisul&te conversion was performed using the Epitect Bisul&te Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol.
Determining CpG methylation levels. PCR and sequencing primers were designed using the 
PyroMark Assay Design 2.0 software (Qiagen, Hilden, Germany). DNA fragments were amplified from 
bisulfite-converted DNA using forward primer 5′ -TGGTTGAAGGGTTATTTAGGG-3′ and biotinylated 
reverse primer 5′ -ACTCTATCCCACCCCTTTT-3′ . !e PCR reaction mixture and cycler program are pro-
vided in the Supplementary material. Bisul&te pyrosequencing was performed on a PyroMark Q96MD pyrose-
quencing system (Qiagen) using the PyroMark Gold Q96 CDT reagent kit (Qiagen) and the Pyro Q-CpG 
so$ware (Qiagen). Percentage of methylation at eleven individual CpG sites within intron 1 of HIF3A were 
determined using three different sequencing primers (Assay 1: 5′ -TTTAGGGGGTGTAGG-3′ ; Assay 2: 
5′ -GGTGAGATGATTTTATAGGAA-3′ ; Assay 3: 5′ -GTTAAGAGGGGTTTTTATT-3′ ). Assay 1 included seven 
CpGs, Assay 2 only one CpG and Assay 3 three CpGs. !e sixth CpG site in Assay 1, the CpG site in Assay 2 and 
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the third CpG site in Assay 3 correspond to the CpG sites on the 450 K array reported elsewhere11. In our expe-
rience, the average methylation dierence between technical replicates is approximately one percentage point.
Genotyping of 	͹ SNPs. Genomic DNA was extracted from blood using the Quick Gene DNA whole 
blood Kit (Kurabo, Japan). Genotyping of the two previously reported SNPs rs8102595 (A/G) and rs3826795 
(G/A)11 was performed using the TaqMan SNP Genotyping assay (Applied Biosystems; C _29247492_10; 
C_31640839_10). To assess genotyping reproducibility, a random ~5% selection of the sample were re-genotyped 
for all SNPs; all genotypes matched initial designated genotypes. Potential functional signicance of the stud-
ied genetic variants was checked using the Regulome Database, which includes public datasets from GEO, the 
ENCODE project, and published literature20.
Total Lean Overweight Obese NGT T2D CRP < 5
N 865 88 73 704 484 343 347
Men/Women 288/577 40/48 36/37 212/492 155/329 124/219 129/218
Age (years) 49 ± 13 62 ± 15aaa 62 ± 14 46 ± 11ccc 47 ± 15ddd 51 ± 10 49 ± 13
BMI (kg/m2) 44.3 ± 12.6 22.1 ± 2.3aaa 27.2 ± 1.3bbb 48.9 ± 9.0ccc 40.9 ± 12.9ddd 49.4 ± 10.8 41.8 ± 11.7eee
Body weight (kg) 129 ± 39 63 ± 9aaa 78 ± 9bbb 142 ± 30ccc 119 ± 41ddd 143 ± 33 122 ± 38eee
Height (m) 1.6 ± 0.1 1.68 ± 0.09 1.69 ± 0.09 1.69 ± 0.09 1.69 ± 0.1 1.69 ± 0.1 1.70 ± 0.09
Waist (cm) 126.8 ± 26.2 77.0 ± 13.7aaa 96.8 ± 13.8bbb 137.1 ± 19.7ccc 116.2 ± 28.2ddd 142.6 ± 22.0 124.0 ± 27.9
Hip (cm) 129.1 ± 28.7 86.3 ± 9.7aaa 102.4 ± 11.4bbb 141.5 ± 21.0ccc 126.0 ± 30.3dd 135.7 ± 24.7 127.0 ± 28.5
WHR 0.95 ± 0.13 0.90 ± 0.11aa 0.94 ± 0.08 0.97 ± 0.14 0.91 ± 0.12ddd 1.05 ± 0.08 0.95 ± 0.13
Visceral Fat area (cm2) 240 ± 172 45 ± 29aaa 119 ± 60bbb 313 ± 154ccc 177 ± 142ddd 392 ± 150 209 ± 175
SC fat area (cm2) 1093 ± 789 52 ± 26aaa 273 ± 171bbb 1509 ± 559ccc 992 ± 817ddd 1386 ± 671 920 ± 814e
CT ratio (vis/sc) 0.4 ± 0.5 1.9 ± 0.9aaa 0.5 ± 0.3bb 0.2 ± 0.1ccc 0.3 ± 0.4 0.5 ± 0.7 0.4 ± 0.5
Body Fat (%) 41.4 ± 11.5 19.0 ± 3.5 24.3 ± 3.9 45.1 ± 8.0 38.5 ± 13.0 44.3 ± 9.4 39.1 ± 11.0
CRP (mg/dl) 11.4 ± 14.4 14.9 ± 22.9 9.1 ± 13.1 11.2 ± 13.1 11.2 ± 15.6 12.1 ± 13.2 2.4 ± 1.5
IL-6 (pg/ml) 6.0 ± 5.2 2.2 ± 3.3 2.8 ± 2.4 7.0 ± 5.3 5.2 ± 4.6 7.5 ± 6.0 4.1 ± 1.3
HbA1c (%) 6.1 ± 1.2 5.3 ± 0.4 5.7 ± 0.6 6.1 ± 1.2 5.5 ± 0.5 6.9 ± 1.4 6.0 ± 1.0
oGTT2h (mmol/l) 7.0 ± 2.6 6.0 ± 1.0 6.1 ± 0.9 7.4 ± 2.9 6.3 ± 1.0 14.8 ± 5.9 6.6 ± 1.7
FPG (mmol/l) 6.5 ± 2.5 5.5 ± 1.0 5.9 ± 1.5 6.7 ± 2.7 5.4 ± 1.0 8.1 ± 3.2 6.1 ± 2.1
FPI (pmol/) 123.1 ± 133.8 10.8 ± 20.6 68.0 ± 92.5 146.4 ± 137.2 62.4 ± 70.8 206.2 ± 156.4 109.7 ± 121.7
GIR (µ mol/kg/min) 75.1 ± 33.4 102.5 ± 18.5 77.7 ± 25.8 56.9 ± 31.2 90.6 ± 21.4 30.5 ± 23.5 85.3 ± 28.3
Total cholesterol (mmol/l) 4.9 ± 1.0 5.1 ± 0.8 5.0 ± 1.1 4.9 ± 1.0 4.9 ± 1.0 4.9 ± 1.0 4.9 ± 1.0
HDL-C (mmol/l) 1.2 ± 0.3 1.7 ± 0.5 1.4 ± 0.3 1.1 ± 0.3 1.3 ± 0.4 1.1 ± 0.3 1.2 ± 0.4
LDL-C (mmol/l) 3.1 ± 0.9 2.8 ± 1.0 3.2 ± 0.8 3.1 ± 0.9 3.1 ± 0.9 3.0 ± 0.8 3.1 ± 0.9
FFA (mmol/l) 0.5 ± 0.4 0.2 ± 0.2 0.3 ± 0.3 0.6 ± 0.3 0.3 ± 0.3 0.8 ± 0.3 0.5 ± 0.3
TG (mmol/l) 1.8 ± 1.1 1.1 ± 0.4aaa 1.2 ± 0.5 1.9 ± 1.1ccc 1.4 ± 0.9ddd 2.1 ± 1.1 1.8 ± 1.1
Leptin (ng/ml) 39.3 ± 24.2 4.8 ± 3.7aaa 12.4 ± 7.0bbb 45.4 ± 21.8ccc 37.1 ± 23.9 41.2 ± 25.0 35.6 ± 22.7e
Adiponectin (µ g/ml) 6.9 ± 4.4 14.3 ± 6.2aaa 8.8 ± 3.5bbb 6.0 ± 3.3ccc 8.5 ± 4.7ddd 4.9 ± 3.1 7.1 ± 4.2
Albumin (g/L) 28.1 ± 18.9 32.9 ± 7.7 34.4 ± 13.2 26.9 ± 20.2 27.1 ± 18.8 28.6 ± 19.6 29.5 ± 20.0
ALAT (µ kat/l) 0.6 ± 0.5 0.4 ± 0.3aaa 0.5 ± 0.3 0.7 ± 0.5ccc 0.6 ± 0.4d 0.7 ± 0.5 0.7 ± 0.4
ASAT (µ kat/l) 0.6 ± 2.3 0.4 ± 0.3 0.4 ± 0.2 0.6 ± 2.5 0.6 ± 3.0 0.6 ± 0.5 0.5 ± 0.3
gGT (µ kat/l) 0.9 ± 1.3 1.0 ± 1.4 1.0 ± 1.5 0.8 ± 1.3 0.8 ± 1.0d 1.0 ± 1.7 0.7 ± 0.9e
TSH (mU/l) 1.9 ± 7.9 1.5 ± 2.1 1.5 ± 1.9 2.1 ± 8.8 1.7 ± 1.8 2.3 ± 12.4 1.4 ± 1.0
fT3 (pg/ml) 4.6 ± 0.9 4.5 ± 1.0 4.4 ± 0.7 4.7 ± 0.9c 4.5 ± 0.9 4.7 ± 0.9 4.6 ± 0.9
fT4 (pmol/l) 17.1 ± 1.4 17.2 ± 3.3 17.5 ± 3.2 16.9 ± 3.5 16.9 ± 3.4d 17.4 ± 3.4 17.6 ± 3.3e
Leucocytes/nl 8.1 ± 2.7 7.5 ± 3.2 7.4 ± 3.1 8.2 ± 2.6c 2.1 ± 0.5 2.1 ± 0.5 7.4 ± 2.2e
Erythrocytes (Mio/µ l) 4.7 ± 0.8 4.6 ± 2.7 4.3 ± 0.9 4.7 ± 0.4 4.7 ± 1.0 4.7 ± 0.4 4.7 ± 0.4
!rombocytes (109/l) 260 ± 81 252 ± 108 241 ± 71 261 ± 79 261 ± 73 259 ± 88 232 ± 66e
Table 1.  Anthropometric and metabolic characteristics of study participants. Data are means ± SD; 
a,b,c,d,ep < 0.05, aa,bb,cc,dd,eep < 0.01, aaa,bbb,ccc,ddd,eeep < 0.001 for comparison between (a) lean and obese, (b) lean 
and overweight, (c) overweight and obese, (d) type 2 diabetes subjects (T2D) and subjects with normal glucose 
tolerance (NGT) and (e) CRP < 5 and the entire cohort. 51 subjects with type 1 diabetes or impaired glucose 
tolerance were not considered for group comparison. BMI – Body Mass Index, WHR – waist-to-hip ratio, sc - 
subcutaneous, TG – Triglycerides, ALAT – alanine aminotransferase, ASAT - aspartate aminotransferase, gGT 
- Gamma-glutamyl transferase, TSH – thyroid-stimulating hormone, fT3 – free triiodothyronine, fT4 – free 
tetraiodothyronine, CRP – C-reactive protein, IL-6 – Interleukin 6, HbA1c – Glycohemoglobin, oGTT – oral 
Glucose Tolerance Test, FPG – Fasting plasma glucose, FPI – Fasting plasma insulin, GIR – Glucose infusion 
rate during the steady state of an euglycemic hyperinsulinemic clamp, HDL-C – high Density Lipoprotein 
Cholesterol, LDL-C – Low Density Lipoprotein Cholesterol, FFA – Free Fatty Acids.
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Statistical Analyses. All non-normally distributed parameters were logarithmically transformed to 
approximate a normal distribution. To analyze dierences in HIF3A methylation/expression levels between vis-
ceral and subcutaneous adipose tissue, paired two-tailed t-tests were applied. To test for group dierences (e.g. 
lean vs. obese, NGT vs. T2D) two tailed t-tests were used. Pearson’s correlation coe!cients were used to assess 
bivariate correlation with phenotypes related to obesity, fat distribution and glucose and insulin homeostasis. 
Linear regression models were used to control for confounders such as age, gender and BMI. To test SNPs for 
genetic associations with mRNA expression, DNA methylation and metabolic traits, linear regression analysis 
adjusted for respective covariates was applied. Association studies on type 2 diabetes (T2D) and obesity (lean 
with BMI < 25 kg/m2 vs. obese with BMI ≥ 30 kg/m2) were done using logistic regression analyses. P-values ≤ 0.05 
were considered to provide nominal evidence for association. Two-sided p-values are reported without adjust-
ments for multiple testing. "e analysis of associations with quantitative traits was restricted to nondiabetic sub-
jects to avoid diabetes status or treatment masking potential eects of the variants on these parameters. Statistical 
analyses were performed using SPSS statistics version 20.0.1 (SPSS, Inc., Chicago, IL, USA).
Results
	͹ mRNA expression is fat depot related. Analysis of paired subcutaneous and visceral adipose 
tissue samples revealed signi#cantly higher HIF3A mRNA expression in subcutaneous compared to visceral adi-
pose tissue (Fig. 1A). "e fat depot dierences in HIF3A expression could be con#rmed in both genders (Fig. 1B). 
"ere was no signi#cant dierence in both subcutaneous and visceral adipose tissue HIF3A mRNA expression 
between individuals with normal glucose tolerance (NGT) and with type 2 diabetes (Supplementary Figure).
We further analyzed the contribution of adipocytes and stromal vascular fraction cells on whole adipose tissue 
HIF3A mRNA expression. Analysis of visceral and subcutaneous stromal vascular fraction showed signi#cantly 
higher HIF3A mRNA levels in subcutaneous compared to visceral stromal vascular fraction (p < 0.05) (subcu-
taneous 0.56 ± 0.84 and visceral 0.37 ± 0.57). In paired samples of adipocytes and stromal vascular fraction cells 
we found signi#cantly higher HIF3A expression in adipocytes compared to stromal vascular fraction cells both 
in subcutaneous and visceral fat compartments (Fig. 1C). "ere was no signi#cant fat depot-related dierence 
in HIF3A mRNA expression of isolated adipocytes. We further sought to determine HIF3A mRNA expression 
Figure 1. HIF3A mRNA expression in human subcutaneous (SAT, n = 584) and visceral (VAT, n = 588) 
adipose tissue. In the entire study cohort (A), but also in subgroups of men (SAT, n = 108; VAT, n = 110) and 
women (SAT, n = 231; VAT, n = 230) (Subjects with T2D were excluded from analysis) (B). Expression of HIF3A 
is signi#cantly higher in subcutaneous (SAT) compared to visceral (VAT) adipose tissue. (C) HIF3A mRNA 
expression in adipocytes (n = 35) and cells of the stromal vascular fraction (SVF). HIF3A is signi#cantly higher 
expressed in adipocytes compared to cells of the SVF in both compartments (D) HIF3A mRNA expression 
in relation to adipocyte cell size in subcutaneous (SAT) and visceral (VAT) adipose tissue. Individuals were 
categorized by mean SAT and VAT adipocyte size into deciles. Comparison of HIF3A mRNA expression between 
individuals with the lowest versus highest mean adipocyte size decile reveals that HIF3A is more highly expressed 
in subjects with higher mean adipocyte volume. Data are presented as means ± SEM. * * p < 0.01, * * * p < 0.001, 
AU-arbitrary units.
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in relation to adipocyte cell size. Comparison of HIF3A mRNA expression between individuals with the lowest 
versus highest mean adipocyte size decile reveals that HIF3A is more highly expressed in subjects with higher 
mean adipocyte volume (Fig. 1D).
	͹ mRNA expression in adipose tissue correlates with parameters of obesity, systemic 
ƪǡ
(leptin, 
). HIF3A mRNA expression in visceral and subcutaneous adipose tissue correlated signif-
icantly with BMI, body weight, waist and hip circumferences, abdominal visceral and subcutaneous fat area, 
%body fat, free fatty acid, triglyceride, alanine aminotransferase (ALAT), leptin serum concentrations and with 
the mRNA expression of Leptin (Table 2 and Supplementary Table 1). Furthermore, there were signi"cant inverse 
correlations between subcutaneous and visceral adipose tissue HIF3A expression and age, CT ratio, adiponectin 
and C-reactive protein (CRP) serum concentrations (Fig. 2A) and leucocyte count (Fig. 2B). Only in visceral 
adipose tissue, HIF3A expression correlated with fasting plasma insulin, thyroid-stimulating hormone (TSH), 
HIF3A mRNA Expression in subcutaneous adipose tissue HIF3A mRNA Expression in visceral adipose tissue
r p-value adj. p-value r p-value adj. p-value
Age (years) − 0.23 4.61 × 10−5 0.032 − 0.237 3.08 × 10−5 0.076
BMI (kg/m2) 0.239 2.86 × 10−5 0.017a 0.283 5.46 × 10−7 8.84 × 10−4a
Body weight (kg) 0.235 5.56 × 10−5 0.467a 0.263 5.45 × 10−6 0.280a
Height (m) 0.044 0.458 0.467 0.001 0.983 0.538
Waist (cm) 0.472 8.41 × 10−9 0.010 0.515 1.89 × 10−10 0.048
Hip (cm) 0.387 2.13 × 10−5 0.425 0.442 6.73 × 10−7 0.628
WHR 0.172 0.067 0.018 0.139 0.135 0.033
Visceral fat area (cm2) 0.391 3.19 × 10−5 0.636 0.442 1.71 × 10−6 0.479
SC fat area (cm2) 0.392 2.99 × 10−5 0.240 0.465 4.06 × 10−7 0.604
CT ratio (sc/vis) − 0.259 7.04 × 10−3 0.165 − 0.319 7.80 × 10−4 0.325
Body fat (%) 0.324 0.017 0.055a 0.442 8.23 × 10−4 0.013a
CRP (mg/dl) − 0.138 0.021 1.8 × 10−3 − 0.153 0.010 3.19 × 10−4
Leucocytes/nl − 0.127 0.032 3.05 × 10−3 − 0.133 0.024 1.13 × 10−3
Met Blood (%) 0.054 0.720 0.618 0.023 0.876 0.772
Met SAT (%) − 0.054 0.687 0.482 − 0.088 0.498 0.345
Met VAT (%) 0.060 0.648 0.667 − 0.045 0.729 0.757
Leptin mRNA sc 0.227 2.82 × 10−4 2.37 × 10−4 0.216 5.28 × 10−4 1.41 × 10−3
Leptin mRNA vis 0.117 0.063 0.043 0.195 2.0 × 10−3 2.60 × 10−3
PPARG mRNA sc 0.001 0.977 0.939 0.002 0.967 0.878
PPARG mRNA vis 0.050 0.253 0.439 0.111 0.010 0.023
Table 2.  Correlation analyses of subcutaneous and visceral adipose tissue HIF3A mRNA expression 
with metabolic parameters, methylation levels and mRNA expression of leptin and PPARG. r - correlation 
coe#cient (Pearson adj. – p-value adjusted to age, sex and BMI), aadjusted for sex and age; BMI – Body Mass 
Index, WHR – waist-to-hip ratio, sc - subcutaneous, CRP – C-reactive protein, Met Blood (%)/Met SAT (%)/
Met VAT (%) - Methylation of cg22891070 in HIF3A in blood/SAT/VAT.
Figure 2. HIF3A mRNA expression in subcutaneous and visceral adipose tissue in relation to CRP serum 
concentration categories (n = 318) and leucocyte counts (n = 326). A signi"cant inverse relationship between 
both CRP level (A) and leucocyte count (B) and expression of HIF3A in both compartments can be observed. 
Data are presented as means ± SEM. * * * p < 0.001, AU-arbitrary units.
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high density lipoprotein (HDL)-cholesterol, gamma glutamyltransferase and the mRNA expression with PPARG 
(p < 0.05; Table 2).
A"er adjusting for age and gender, correlations between visceral and subcutaneous adipose tissue HIF3A 
mRNA expression and BMI, but also between visceral HIF3A mRNA expression and %body fat remained sig-
nicant (Table 2). Correlations between subcutaneous and visceral adipose tissue HIF3A mRNA expression and 
waist, WHR, CRP level, leucocyte count and leptin mRNA expression remained signicant a"er adjusting for 
age, gender and BMI (Table 2). A"er adjusting for covariates, free fatty acids only correlated with subcutaneous 
HIF3A mRNA expression and visceral HIF3A mRNA levels correlated with visceral mRNA expression of PPARG. 
In both fat depots, we found decreased HIF3A mRNA expression with increasing subcategories of both CRP 
serum concentrations and leucocyte counts (Fig. 2). To avoid a potential bias of systemic in$ammation on HIF3A 
expression and its associations with anthropometric and metabolic traits, we performed correlation analyses only 
in individuals with CRP < 5mg/dl; however, the data remained unchanged (data not shown).
;ͷͶ͸ͻͿͻ͹;͸ͼͽͿͻ	͹ DNA methylation, mRNA expression and 
metabolic traits. In the present study, we included 2 SNPs (rs8102595 and rs3826795) which have pre-
viously been shown to be associated with DNA methylation in a large cohort including > 200011. Both stud-
ied polymorphisms were in Hardy-Weinberg Equilibrium (p > 0.05) with following minor allele frequencies: 
rs8102595-10.8%, rs3826795-21.6%. &ere was no signi#cant association between the SNPs and HIF3A mRNA 
expression in any of the two adipose tissue depots (Table 3). However, rs8102595 was nominally associated with 
HIF3A DNA methylation in visceral and subcutaneous adipose tissue (p < 0.05 a"er adjusting for age, gender 
and BMI; Table 3). Subjects carrying the minor allele (G) had a higher HIF3A DNA methylation in visceral 
adipose tissue, which was in line with the lower HIF3A mRNA expression in visceral adipose tissue (albeit not 
signi#cant). Association analyses with parameters of obesity and fat distribution revealed a nominal association 
between rs3826795 and total cholesterol and the mean fat cell size of visceral adipose tissue (Supplementary Table 
2). Rs8102595 showed an association with HDL-cholesterol, glucose in#ltration rate and maximum fat cell size of 
subcutaneous adipose tissue (Table 3 and Supplementary Table 2).
rs8102595 rs3826795
A/A A/G + G/G p-value A/A+ A/G G/G p-value
N 446 95 208 336
Men/Women 151/295 32/63 73/135 110/226
Age 52.83 ± 15.79 55.48 ± 15.44 0.482 49.56 ± 15.31 50.72 ± 14.69 0.278
BMI (kg/m2) 43.48 ± 13.74 42.51 ± 13.50 0.239 43.64 ± 14.04 42.93 ± 13.32 0.908
Body weight (kg) 126.86 ± 42.81 124.57 ± 40.14 0.680 128.42 ± 45.54 124.60 ± 41.15 0.769
Height (m) 1.69 ± 0.09 1.69 ± 0.9 0.628 1.69 ± 0.09 1.69 ± 0.09 0.763
Waist (cm) 124.26 ± 29.98 121.84 ± 30.09 0.798 124.46 ± 30.43 122.85 ± 29.87 0.935
Hip (cm) 130.53 ± 28.99 128.59 ± 28.38 0.851 129.54 ± 28.38 130.08 ± 29.56 0.676
WHR 0.95 ± 0.13 0.96 ± 0.16 0.316 0.96 ± 0.16 0.94 ± 0.12 0.921
VAT area (cm2) 242.93 ± 173.84 237.02 ± 159.92 0.575 256.05 ± 183.40 228.98 ± 159.97 0.674
SAT area (cm2) 1095.74 ± 795.48 1129.73 ± 819.78 0.536 1122.85 ± 774.80 1094.46 ± 817.64 0.902
VAT mean 123.00 ± 20.82 122.08 ± 20.60 0.999 119.69 ± 25.71 124.66 ± 17.25 0.014
SAT mean 127.37 ± 19.89 127.51 ± 17.42 0.486 126.50 ± 19.04 127.99 ± 19.84 0.334
VAT max 209.23 ± 58.51 230.21 ± 96.06 0.060 210.73 ± 74.84 213.66 ± 63.47 0.109
SAT max 214.28 ± 70.88 249.22 ± 110.69 1.23 × 10−3 224.71 ± 80.22 217.94 ± 79.94 0.987
CT ratio (vis/sc) 0.47 ± 0.63 0.38 ± 0.30 0.922 0.40 ± 0.42 0.48 ± 0.66 0.826
Body fat (%) 41.95 ± 11.35 42.26 ± 11.72 0.496 41.15 ± 11.88 42.57 ± 11.11 0.607
CRP (mg/dl) 12.04 ± 15.09 11.20 ± 16.05 0.935 13.09 ± 15.67 11.34 ± 15.49 0.198
Leucocytes/nl 8.21 ± 2.88 8.08 ± 2.50 0.743 8.42 ± 3.22 8.00 ± 2.48 0.155
Blood Met (%) 20.99 ± 8.07 22.31 ± 5.11 0.143 21.43 ± 7.36 21.27 ± 7.56 0.811
Met SAT (%) 11.95 ± 5.86 16.34 ± 6.54 0.011 13.56 ± 7.38 12.69 ± 5.83 0.784
Met VAT (%) 17.04 ± 5.61 19.69 ± 6.10 0.038 18.20 ± 4.41 17.46 ± 6.18 0.401
SAT HIF3A mRNA 21.08 ± 72.62 7.43 ± 40.53 0.209 11.58 ± 49.82 22.60 ± 76.47 0.660
VAT HIF3A mRNA 23.92 ± 106.19 10.45 ± 50.03 0.073 16.80 ± 82.25 24.09 ± 106.69 0.729
Table 3.  Association of rs8102595 and rs3826795 with anthropometric and metabolic characteristics, 
mRNA expression and DNA methylation. Due to the low minor allele frequency (MAF) of the studied 
polymorphisms, subjects homozygous for the minor alleles (n = 3 for rs8102595, n = 16 for rs3826795) were 
combined with heterozygous groups (i.e. dominant mode of inheritance was used for statistical analyses). 
p-value adjusted for age, gender and BMI and diabetes status; BMI – Body Mass Index, WHR – waist-to-hip 
ratio, SAT – subcutaneous adipose tissue, VAT- visceral adipose tissue CRP – C-reactive protein, Met Blood 
(%)/Met SAT (%)/Met VAT (%) - Methylation of cg22891070 in HIF3A in blood/SAT/VAT, HIF3A mRNA – 
mRNA expression of HIF3A in subcutaneous/visceral adipose tissue.
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	͹ DNA methylation in blood, subcutaneous and visceral adipose tissue. Methylation 
measured at the CpG site in Assay 2, corresponds to the published cg22891070, which has been reported to 
show the strongest correlation to BMI11. In our study, HIF3A DNA methylation at cg22891070 was signi!cantly 
higher in blood (20.84 ± 7.74%) compared to subcutaneous (12.83 ± 6.82%; p < 0.001) and visceral adipose tis-
sue (17.28 ± 5.61%; p < 0.001), whereas HIF3A DNA methylation in visceral adipose tissue was signi!cantly 
higher than in subcutaneous adipose tissue (p <  0.001; Fig. 3A). In addition, DNA methylation at cg22891070 in 
visceral adipose tissue correlated signi!cantly with hip (p < 0.01, r = 0.614), subcutaneous (p < 0.01, r = 0.651) 
and visceral fat mass (p < 0.05, r = 0.468) and inversely with the CT-ratio (p < 0.01, r = − 0.653). Correlations 
between methylation in visceral adipose tissue and subcutaneous fat mass (p < 0.01), CT ratio (p < 0.01), hip 
(p < 0.01) and adiponectin (p < 0.05, r = − 0.187) remained signi!cant even a#er adjusting for age, gender and 
BMI. Furthermore, methylation of cg22891070 in subcutaneous adipose tissue correlated with CT ratio (p < 0.05, 
r = − 0.571) and age (p < 0.05, r = − 0.268). A#er adjusting for gender and BMI the correlation remained sig-
ni!cantly for age (p = 0.032). Albeit not signi!cant, in all analyzed tissues, obese individuals displayed a higher 
methylation of cg22891070 compared to lean and overweight individuals (Fig. 3B). $e analyses including other 
tested CpG sites did not reveal correlations beyond those observed for cg22891070 (data not shown).
Discussion
Recent studies revealed an association between BMI and methylation of HIF3A in whole blood and in adipose 
tissue11–13. It has been proposed that the HIF-system could play a role in mechanisms involved in the patho-
physiology of adipose tissue-in&ammation, obesity-induced insulin resistance and the etiology of obesity related 
diseases. We therefore sought to further elucidate the relationship between HIF3A mRNA expression in visceral 
and subcutaneous adipose tissue and obesity, but also methylation of CpG-sites in HIF3A. In summary, we show 
that HIF3A gene expression and methylation in adipose tissue are fat depot speci!c, and related to obesity and 
adipose tissue dysfunction.
We investigated the methylation and expression of HIF3A in two distinct fat depots, subcutaneous and vis-
ceral adipose tissue. We show that higher HIF3A mRNA expression in both subcutaneous and visceral adipose 
tissue is associated with higher BMI and obesity related traits. HIF3A has been shown to accelerate 3T3-L1 adi-
pocyte di'erentiation and to induce the expression of adipocyte related genes9. Interestingly, we found higher adi-
pose tissue HIF3A mRNA expression in individuals of the highest decile of mean adipocyte size (for both depots) 
compared to the lowest decile. $is may suggest that HIF3A is involved in the determination of adipocyte size and 
may thereby contribute to adipose tissue expandability. Our results further support the hypothesis that expres-
sion of HIF3A might be induced in states of metabolic excess and mediate mechanisms involved in adipogenesis. 
Moreover, based on our data, the expression of HIF3A seems to be more pronounced in adipocytes compared to 
the stromal vascular fraction independent of the fat depot. To this end, adipocytes isolated from subcutaneous 
adipose tissue displayed higher expression levels of HIF3A than those isolated from visceral adipose tissue. $us, 
the major proportion of HIF3A expression in adipose tissue might be attributed to primary adipocytes, which 
further supports the proposed regulatory role of HIF3A in adipogenesis. In further support of this, we found a 
positive correlation between the mRNA expression of HIF3A and leptin (in both visceral and subcutaneous adi-
pose tissue) as well as PPARG (in visceral adipose tissue), two genes involved in the regulation of adipogenesis.
It is noteworthy, that HIF3A expression inversely correlated with CRP level and leucocyte count, suggesting 
down-regulation of the HIF3A expression in in&ammatory states. Chronic in&ammation in adipose tissue, liver 
and skeletal muscle are commonly associated with obesity2, which results in secondary pathologies like insu-
lin resistance, hyperinsulinemia and glucose intolerance3,21. Obesity promoted relative hypoxia in adipocytes 
stimulates HIF1A-induction5,6, which then triggers the in&ammation process by mediating the production of 
adipocyte-derived chemokines and adipose tissue macrophage accumulation4,7. HIF3A can inhibit HIF1A medi-
ated signaling under certain circumstances22. $e observed reduced expression of HIF3A in in&ammatory states 
may facilitate increased HIF1A signaling, which in turn could activate an in&ammatory cascade within adipose 
tissue.
Figure 3. Methylation of cg22891070 in HIF3A in di!erent tissues and in relation to BMI (n = 87). $e 
HIF3A locus is signi!cantly higher methylated in blood compared to SAT and VAT (A) $e di'erence in 
methylation levels can be observed for all BMI groups (B) Methylation levels are higher in subjects with 
increased BMI (B). Data are presented as means ± SEM. * p < 0.05, * * p < 0.01, * * * p < 0.001.
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HIF3A mRNA expression is regulated at dierent levels. Transcription of HIF3A can be induced by HIF1 via 
hypoxia response elements (HREs) in the promoter region and protein stability of HIF3α can be regulated in 
dependency of oxygen supply via the oxygen-dependent degradation domain (ODD)22–24. HIF3A expression has 
further been shown to be regulated by micro RNA (miRNA), thus to be modi!ed on a post-transcriptional level25. 
"ese dierent mechanisms can supplement one another in !ne tuning of HIF3A expression. We hypothesize that 
the complex regulation of HIF3A expression can be in#uenced by DNA methylation in various ways by interfer-
ing with dierent mechanisms of regulation. An association between BMI and methylation at three CpG-sites in 
intron 1 of HIF3A in whole blood and in adipose tissue has recently been identi!ed by employing genome-wide 
DNA-methylation analyses11–13. In contrast, we did not !nd a correlation between BMI and HIF3A methylation. 
"is may be due to the smaller sample size and a dierent composition of our cohort, which is characterized by a 
relatively high BMI (32.9 kg/m2), and thus, strongly diering from the previously reported cohorts with average 
BMI ranging between 24.2 and 28.3 kg/m2. Rönn et al. were able to replicate the association between methylation 
of HIF3A and BMI in a female cohort only12 and Demerath et al. showed HIF3A methylation to be associated 
with BMI only in one of three cohorts investigated13. Considering multiple isoforms of HIF3α 8, it is plausible that 
methylation might be transcript-speci!c; yet, one would expect to observe consistent results upon expression 
analysis of the same transcript.
It is of note that the CpG sites at the HIF3A locus that were associated with BMI are situated within regions of 
open chromatin, suggesting that these sites lie in a regulatory region11,26. However, this regulation appears more 
complex than being dependent on methylation only. It is plausible that methylation of HIF3A results in altered 
expression pro!les, networking with mechanisms in dierent stages of regulation. Yet, a linear eect between 
methylation and expression even of the same transcript cannot be con!rmed.
Methylation analysis of HIF3A in our cohort revealed signi!cant dierences between methylation in blood, 
subcutaneous and visceral adipose tissue, being strongest in blood and weakest in subcutaneous adipose tissue. 
Since HIF3A mRNA expression in subcutaneous adipose tissue is higher than in visceral adipose tissue, it is 
possible that methylation could together with other regulatory mechanisms, cause a decrease in the expression 
of HIF3A. In line with this, rs8102595 was nominally associated with DNA methylation at cg22891070 in sub-
cutaneous and visceral adipose tissue; thus supporting data by Dick et al.11 reporting associations of 2 SNPs 
(rs8102595 and rs3826795) with DNA methylation. Based on the Regulome Database20, rs3826795 might aect 
the binding of transcription factors POLR2A and SIN3A, and rs8102595 might in#uence DNA-protein binding. 
However, considering the lack of associations of the two SNPs with BMI, changes in HIF3A methylation seem to 
be mediated by obesity rather than promoting obesity itself11. It is also of note, that we did not observe an associ-
ation between the SNPs and HIF3A mRNA expression in any of the two adipose tissue depots. We have to point 
out however, that the availability of the biomaterial (adipose tissue and blood samples) only allowed including 548 
subjects for genotyping and for subsequent genotype-expression association analyses, which may have resulted in 
the lack of statistical power for correlation analyses.
In contrast to previous studies mostly investigating subcutaneous adipose tissue, the present study reveals 
mRNA expression and DNA methylation dierences between subcutaneous and visceral adipose tissue. "e two 
depots consist of dierent histological and biochemical compounds. "e depot-speci!c expression of HIF3A 
may be important for the dierent functioning of the dierent depots. Whereas visceral adipose tissue is more 
vascular, innervated and contains a higher number of in#ammatory and immune cells, subcutaneous adipose 
tissue has a higher preadipocyte dierentiating capacity and a lower percentage of large adipocytes27. As HIF3A 
mRNA expression is higher in subcutaneous adipose tissue, possibly due to dierences in methylation, this con-
tributes to our assumption that HIF3α might be involved in preadipocyte dierentiation, and that this process 
may be regulated by methylation, along with other factors. It is noteworthy that recently, we observed diminished 
hydroxymethylation levels in subcutaneous adipose tissue, as a measure of potential de-methylation mechanisms, 
which might be related to the higher number of pre-adipocytes in subcutaneous adipose tissue28.
We found methylation of HIF3A in both compartments to be correlated inversely with fat distribution, and methyla-
tion in VAT correlated signi!cantly with subcutaneous fat mass. "is suggests that methylation occurs rather in subjects 
with a preponderance of subcutaneous fat. We also detected an inverse association between age and methylation in sub-
cutaneous adipose tissue, which leads to the assumption that the modi!cation is dynamic and changes during lifetime.
Finally, it has to be acknowledged that the CpG site cg22891070 presented in our study is located between the 
2 previously reported CpG islands11. Various HIF3A transcripts with dierent functions have been reported22 
and it is also likely that they can be speci!cally aected by the methylation. Since the expression assay used in the 
present study tagged all potential HIF3A transcripts, we were not able to link cg22891070 to a speci!c transcript. 
However, in our own datasets based on genome-wide expression arrays (unpublished data) transcript variants 2 
(NM_022462.4) and 3 (NM_152795.3) seem to be predominantly expressed in adipose tissue. Since Pasanen et al.22  
suggested no functional relevance of the variant 3, it remains to be determined whether transcript variant 2 
appears functionally relevant in adipose tissue.
In conclusion, our data suggest that HIF3A expression and methylation in adipose tissue is related to its dys-
function, making HIF3A an important factor involved in the complex etiology of obesity and associated comor-
bidities. HIF3A might function as an accelerator of adipogenesis in situations of excess of energetic supply and 
might contribute to the etiology of secondary obesity-induced pathologies by allowing a stronger induction of 
HIF1α -mediated proin#ammatory signaling.
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Introduction 
Obesity and its associated comorbidities constitute an evolving health burden worldwide 
(113). Obesity conditions chronic inflammation in adipose tissue, liver and skeletal muscle 
(44), which may contribute to chronic systemic inflammation, insulin resistance, and 
deterioration in glucose and lipid metabolism (46). 
Upon weight gain, adipocyte hypertrophy may lead to hypoxia in adipose tissue (AT) which 
could be considered as a causative factor in the development of AT inflammation (45, 33, 
114, 43). In this context, it has been recently shown that AT expression of hypoxia inducible 
factor 1A (HIF1A), a hypoxia inducible transcription factor, increases in mice early upon 
weight gain (52). In states of relative adipocyte hypoxia, induction of HIF1A (53, 54), 
stimulates accumulation of AT macrophages (55, 52) and the production of adipocyte-
derived pro-inflammatory cytokines.  
Hypoxia-inducible factors are transcription factors that mediate hypoxia response in various 
tissues (53). They are heterodimeric transcription factors consisting of an oxygen-labile α-
subunit and a constitutively expressed β-subunit. Three different isoforms of the α-subunit, 
HIF1α, HIF2α and HIF3α, exist and allow the formation of transcription factors with 
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different functions upon dimerizing with HIFβ. The HIF1α and HIF2α target genes allow 
regulation of various biological processes such as erythropoiesis, angiogenesis, metabolic 
reprogramming, cell-cycle-regulation, and tumor progression, displaying master regulators 
of the transcriptional response to hypoxia (56, 57). HIF3α structurally and functionally 
differs from HIF1α/2α (71, 72). According to a recent study, HIF3α is capable of activating 
certain target genes independent or in collaboration with HIF1α, suggesting a role of HIF3α 
in glucose and amino acid metabolism, apoptosis, proteolysis, p53 signaling and PPAR 
signaling (78). In addition, HIF3α has been shown to play a role in adipocyte differentiation 
(79).  
Recent genome-wide analyses of DNA methylation in whole blood and human adipose 
tissue revealed an association of methylation at three CpG sites in intron 1 of HIF3A with 
BMI (104–106). In addition, two single nucleotide polymorphisms (SNPs) have been shown 
to be associated with methylation at these sites, yet to be independent of BMI (105). Further 
investigation of the relationship between hypoxia inducible factors and development of 
obesity-associated comorbidities might reveal important insights in pathophysiological 
processes concerning adipose tissue inflammation and/or insulin resistance in the etiology 
of obesity related metabolic diseases.  
 
Objective 
We therefore tested the hypothesis that expression of HIF3A in human subcutaneous and 
visceral AT is related to BMI, parameters of fat distribution and AT function, metabolic 
traits, genetic variation and methylation of CpG-sites in HIF3A. 
 
Design and Methods 
In paired samples of subcutaneous AT (SAT) and visceral AT (VAT) from 603 individuals 
with a wide range of age, BMI and obesity-related parameters, we investigated whether 
HIF3A mRNA expression is fat depot-specific, altered in obesity and related to measures of 
AT function and insulin sensitivity. We further tested for correlations between mean 
adipocyte size and AT HIF3A mRNA expression. In a subgroup of 548 individuals, we 
investigated the effects of HIF3A genetic variants on HIF3A AT expression and HIF3A 
methylation of CpG-sites. Further, we analyzed HIF3A mRNA expression in isolated 
adipocytes and cells from the stromal vascular fraction (SVF, i.e. preadipocytes, endothelial 
cells, endothelial smooth muscle cells, fibroblasts, macrophages, and blood cells isolated 
from adipose tissue). Methods are described in detail in the supplements. 
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Results  
HIF3A expression is significantly higher in SAT compared to VAT and correlates in both 
fat depots with parameters of obesity, glucose metabolism and mRNA expression of genes 
regulating adipogenesis. AT HIF3A expression negatively correlates with circulating CRP 
and leucocytes independently of BMI (p<0.001). HIF3A methylation at cg22891070 is 
significantly higher in VAT compared to SAT and correlates with BMI, abdominal SAT and 
VAT area. Rs8102595 shows a significant association with subcutaneous and visceral 
HIF3A methylation levels and rs3826795 and rs8102595 associate with obesity and fat 
distribution related traits. HIF3a mRNA expression in individuals with the highest decile of 
mean adipocyte size is higher compared to the lowest decile in both depots. We found 
significantly higher HIF3A expression in adipocytes compared to cells of the SVF in both 
SAT and VAT. 
 
Discussion 
We show that HIF3A gene expression and methylation in adipose tissue are fat depot 
specific, related to obesity and adipose tissue dysfunction parameters. Higher HIF3A mRNA 
expression in both subcutaneous and visceral adipose tissue is associated with higher BMI 
and obesity related traits. Our results further support the hypothesis that HIF3A signaling 
might be involved in adipogenesis and in the determination of adipocyte size. HIF3A 
expression is more pronounced in adipocytes compared to cells of the stromal vascular 
fraction, suggesting that the major proportion of HIF3A expression in adipose tissue might 
be attributed to primary adipocytes. We were also able to show a positive correlation 
between the mRNA expression of HIF3A and leptin (in both visceral and subcutaneous 
adipose tissue) and PPARG (in visceral adipose tissue), further supporting the proposed 
regulatory role of HIF3α in adipogenesis. Our data support the hypothesis that hypoxia 
inducible transcription factor pathways may play an important role in the development of 
AT dysfunction associated with obesity. HIF3A gene expression inversely correlated with 
CRP level and leucocyte count, suggesting a down-regulation of HIF3A expression in 
inflammatory states. As HIF3α can inhibit HIF1α mediated signaling under certain 
circumstances, the reduced expression of HIF3A in inflammatory states may facilitate 
increased HIF1A signaling, which in turn activates the inflammatory cascade within adipose 
tissue.  
HIF3A mRNA expression is regulated at different levels. Methylation analysis of HIF3A in 
our cohort revealed significant differences between methylation in blood, subcutaneous and 
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visceral adipose tissue, being strongest in blood and weakest in subcutaneous adipose tissue. 
Since HIF3A mRNA expression in subcutaneous adipose tissue is higher in visceral adipose 
tissue, it is possible that methylation could together with other regulatory mechanisms, cause 
a decrease in the expression of HIF3A. We found methylation of HIF3A in both 
compartments to be correlated inversely with fat distribution, and methylation in VAT 
correlated significantly with subcutaneous fat mass. This suggests that methylation occurs 
rather in subjects with a preponderance of subcutaneous fat. We also detected an inverse 
association between age and methylation in subcutaneous adipose tissue, which leads to the 
assumption that the modification is dynamic and changes during lifetime.  
rs8102595 was associated with DNA methylation at cg22891070 in subcutaneous and 
visceral adipose tissue. However, we did not observe an association between rs8102595 or 
rs3826795 with BMI, suggesting that changes in HIF3A methylation seem to be mediated 
by obesity rather than promoting obesity itself. 
In conclusion, our data suggest that HIF3A expression and methylation in adipose tissue is 
related to its dysfunction, making HIF3α an important factor in the complex etiology of 
obesity and associated comorbidities. 
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4 Supplemental material 
4.1 Material and methods 
Analysis of human HIF3A mRNA expression  
Briefly, human HIF3A mRNA expression was measured by qRT-PCR using TaqMan Gene 
Expression Assay (Applied Biosystems, Darmstadt, Germany), and fluorescence was 
detected on a TaqMan Quant Studio 6 Flex Real-Time PCR-System (Applied Biosystems, 
Darmstadt, Germany). Total RNA was isolated from AT samples using the Qiacube System 
(Qiagen, Hilden, Germany), and 2 µg RNA were reverse transcribed with standard reagents 
(Life Technologies). From each RT-PCR, 2µl was amplified in a 20µl PCR using the 
Taqman Gene Expression Assay (Applied Biosystems, Darmstadt, Germany) and the 
TaqMan Fast Advanced Mastermix (Applied Biosystems, Darmstadt, Germany). Samples 
were incubated in the Quant Studio 6 Flex Real-Time PCR-System (Applied Biosystems, 
Darmstadt, Germany) for an initial denaturation at 95°C for 20s, followed by 45 PCR cycles, 
each cycle consisting of 95°C for 1s and 60°C for 20s. The following Gene Expression Assay 
was used: Hs00541709_M1 (tagging the transcripts NM_022462.4, NM_152794.3, 
NM_152795.3 and NM_152796.4). HIF3A mRNA expression was calculated relative to the 
mRNA expression of HPRT1, determined by a premixed assay on demand for HPRT1 
mRNA (Hs01003267_M1, Applied Biosystems, Darmstadt, Germany). Expression of 
HIF3A and HPRT1 mRNA were quantified by using the second derivative maximum method 
of the TaqMan Software (Applied Biosystems).  
For expression analysis of HIF3A in adipocytes and SVF, total RNA was isolated from 
adipocytes and SVF extracted from paired samples of SAT and VAT. 305 ng RNA were 
reverse transcribed with standard reagents and from each RT-PCR, 23.5µl was amplified in 
a 40µl PCR using the Taqman Gene Expression Assay and the TaqMan Fast Advanced 
Mastermix according to the manufacturer’s instruction. HIF3A mRNA expression was 
calculated relative to the mRNA expression of hypoxanthine guanine 
phosphoribosyltransferase 1 (HPRT1) mRNA or 18S rRNA (for isolated adipocytes only), 
determined by a premixed assay on demand (Hs01003267_m1; Applied Biosystems, 
Darmstadt, Germany). 
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DNA extraction and bisulfite conversion 
Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, 
Germany) and bisulfite conversion was performed using the Epitect Bisulfite Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. PCRs were carried out to 
amplify DNA fragments for pyrosequencing. The following primers were used (Metabion, 
Martiensried, Germany): Forward 5’-TGGTTGAAGGGTTATTTAGGG-3’; reverse 
carrying a biotin label at its 5’-end 5’-ACTCTATCCCACCCCTTTT-3’. The PCR reaction 
mixture for pyrosequencing consisted of 5 µl 10x PCR buffer with MgCl2 (Roche 
Diagnostics, Mannheim, Germany), 1 µl (10 mM dNTPs) PCR Grade Nucleotide Mix 
(Roche Diagnostics), 2.5 µl (10 pmol/µl) of forward and reverse primer (Metabion, 
München-Planegg, Germany), 0.4 µl (5 U/µl) FastStart Taq DNA Polymerase (Roche 
Diagnostics), 2 µl of bisulfite-converted DNA and 36.6 µl PCR-grade water. Amplifications 
were performed with an initial denaturation step at 95°C for 5 min, 38 cycles of 95°C for 30 
s, 60°C for 30 s, and 72°C for 45 s, and a final extension step at 72°C for 5 min. 
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4.2 Results 
Supplementary Table 1. Correlation analyses between subcutaneous and visceral 
adipose tissue HIF3A mRNA expression and study parameters.  
Supplementary table 1. r - correlation coefficient (Pearson adj. – p-value adjusted to age, gender and BMI, a 
adjusted for gender and age; BMI – Body Mass Index, WHR – waist-to-hip ratio, CRP –  C-reactive protein, 
FPI – fasting plasma insulin, HDL-C – high density lipoprotein cholesterol, FFA – free fatty acids, TG – 
triglycerides, ALAT – alanine aminotransferase, gGT - gamma-glutamyl transferase, TSH – thyroid-
stimulation hormone, Met Blood (%)/  Met SAT (%) /  Met VAT (%) - methylation of cg22891070 in HIF3A 
in blood / SAT/ VAT  
  
HIF3A mRNA Expression 
 in subcutaneous adipose tissue 
HIF3A mRNA Expression    
in visceral adipose tissue 
  r p-value adj. p-value r p-value adj. p-value 
Age (years) -0.23 4.61x10-5 0.032 -0.237 3.08x10-5 0.076 
BMI (kg/m²) 0.239 2.86x10-5 0.017a 0.283 5.46x10-7 8.84x10-4a 
Body weight (kg) 0.235 5.56x10-5 0.467a 0.263 5.45x10-6 0.280a 
Height (m) 0.044 0.458 0.467 0.001 0.983 0.538 
Waist (cm) 0.472 8.41x10-9 0.010 0.515 1.89x10-10 0.048 
Hip (cm) 0.387 2.13x10-5 0.425 0.442 6.73x10-7 0.628 
WHR 0.172 0.067 0.018 0.139 0.135 0.033 
Visceral fat area 
(cm²) 0.391 3.19x10-5 0.636 0.442 1.71x10-6 0.479 
SC fat area (cm²) 0.392 2.99x10-5 0.240 0.465 4.06x10-7 0.604 
CT ratio (sc/vis) -0.259 7.04x10-3 0.165 -0.319 7.80x10-4 0.325 
Body fat (%) 0.324 0.017 0.055a 0.442 8.23x10-4 0.013 
CRP (mg/dl) -0.138 0.021 1.8x10-3 -0.153 0.010 3.19x10-4 
FPG (mmol/l) 0.077 0.200 0.180 0.017 0.770 0.784 
FPI (pmol/l) 0.130 0.181 0.161 0.250 8.21x10-3 0.634 
 Total Cholesterol 
(mmol/l) -0.017 0.827 0.673 -0.010 0.891 0.586 
HDL-C (mmol/l) -0.138 0.141 0.913 -0.211 0.022 0.602 
LDL-C 0.109 0.249 0.896 0.111 0.236 0.802 
FFA (mmol/l) 0.442 1.99x10-5 8.97x10-3 0.401 1.43x10-4 0.063 
TG (mmol/l) 0.218 3.40x10-3 0.085 0.196 7.63x10-3 0.262 
Leptin (ng/ml) 0.413 2.14x10-5 0.866 0.461 1.78x10-6 0.918 
Adiponectin (µg/ml) -0.290 3.47x10-3 0.415 -.0348 4.09x10-4 0.241 
Albumin (g/L) -0.328 0.072 0.159 -0.217 0.225 0.015 
ALAT (µkat/l) 0.176 3.31x10-3  0.303 0.135 0.023 0.980 
gGT (µkat/l) -0.101 0.095 0.226 -0.148 0.014 0.040 
TSH (mU/l) 0.091 0.153 0.850 0.128 0.043 0.471 
Leucocytes/nl -0.127 0.032 3.05x10-3 -0.133 0.024 1.13x10-3 
Met Blood (%) 0.054 0.720 0.618 0.023 0.876 0.772 
Met SAT (%) -0.054 0.687 0.482 -0.088 0.498 0.345 
Met VAT (%) 0.060 0.648 0.667 -0.045 0.729 0.757 
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Supplementary Table 2. Association of rs8102595 and rs3826795 with anthropometric 
and metabolic characteristics, mRNA expression and DNA methylation.  
     rs8102595     rs3826795   
  A/A A/G + G/G p-value A/A+ A/G G/G  p-value 
N 446 95  208 336  
Men/Women 151/295 32/63  73/135 110/226  
Age 52.83±15.79 55.48±15.44 0.482 49.56±15.31 50.72±14.69 0.278 
BMI (kg/m²) 43.48±13.74 42.51±13.50 0.239 43.64±14.04 42.93±13.32 0.908 
Body weight (kg) 126.86±42.81 124.57±40.14 0.680 128.42±45.54 124.60±41.15 0.769 
Height (m) 1.69±0.09 1.69±0.9 0.628 1.69±0.09 1.69±0.09 0.763 
Waist (cm) 124.26±29.98 121.84±30.09 0.798 124.46±30.43 122.85±29.87 0.935 
Hip (cm) 130.53±28.99 128.59±28.38 0.851 129.54±28.38 130.08±29.56 0.676 
WHR 0.95±0.13 0.96±0.16 0.316 0.96±0.16 0.94±0.12 0.921 
VAT area (cm²) 242.93±173.84 237.02±159.92 0.575 256.05±183.40 228.98±159.97 0.674 
SAT area (cm²) 1095.74±795.48 1129.73±819.78 0.536 1122.85±774.80 1094.46±817.64 0.902 
VAT mean 123.00±20.82 122.08±20.60 0.999 119.69±25.71 124.66±17.25 0.014 
SAT mean 127.37±19.89 127.51±17.42 0.486 126.50±19.04 127.99±19.84 0.334 
VAT max 209.23±58.51 230.21±96.06 0.060 210.73±74.84 213.66±63.47 0.109 
SAT max 214.28±70.88 249.22±110.69 1.23x10-3 224.71±80.22 217.94±79.94 0.987 
CT ratio (vis/sc) 0.47±0.63 0.38±0.30 0.922 0.40±0.42 0.48±0.66 0.826 
Body fat (%) 41.95±11.35 42.26±11.72 0.496 41.15±11.88 42.57±11.11 0.607 
CRP (mg/dl) 12.04±15.09 11.20±16.05 0.935 13.09±15.67 11.34±15.49 0.198 
IL-6 (pg/ml) 6.05±5.24 5.17±3.71 0.880 6.16±4.54 5.79±5.39 0.286 
HbA1C (%) 6.07±1.11 5.82±0.86 0.443 6.00±1.10 6.02±1.05 0.766 
oGTT2h (mmol/l) 6.99±2.41 7.49±3.97 0.663 7.57±3.40 6.74±2.22 0.064 
FPG (mmol/l) 6.34±2.17 5.83±0.98 0.827 6.34±2.45 6.22±1.77 0.904 
FPI (pmol/) 131.78±141.75 107.18±98.96 0.297 124.28±118.40 127.54±145.26 0.729 
GIR (µmol/kg/min) 75.66±33.87 65.78±35.86 0.042 73.75±33.57 73.58±35.24 0.567 
Total cholesterol  
(mmol/l) 
4.87±0.99 4.72±097 0.130 4.99±1.06 4.75±0.93 0.019 
HDL-C (mmol/l) 1.24±0.41 1.22±0.46 0.027 1.25±0.40 1.23±0.42 0.418 
LDL-C (mmol/l) 3.11±0.94 3.02±1.12 0.143 3.19±1.02 3.01±0.93 0.167 
FFA (mmol/l) 0.58±0.41 0.54±0.39 0.525 0.57±0.43 0.57±0.39 0.076 
TG (mmol/l) 1.65±0.89 1.49±0.66 0.654 1.69±0.96 1.58±0.78 0.444 
Leptin (ng/ml) 37.12±22.14 40.64±23.96 0.313 35.43±21.13 39.15±23.34 0.655 
Adiponectin (µg/ml) 7.93±4.97 6.59±3.36 0.091 7.17±4.67 8.11±4.75 0.095 
Albumin (g/l) 40-95±9.62 40.59±9.43 0.648 39.37±10.74 41.84±8.40 0.086 
ALAT (µkat/l) 0.65±0.50 0.58±0.49 0.360 0.65±0.53 0.62±0.47 0.767 
ASAT (µkat/l) 0.71±3.18 0.52±0.31 0.382 0.89±0.65 0.54±0.28 0.742 
gGT (µkat/l) 0.89±1.65 0.81±0.77 0.679 0.85±1.33 0.88±1.64 0.960 
TSH (mU/l) 2.317±10.87 1.735±2.64 0.296 2.96±15.74 1.73±2.06 0.071 
fT3 (pg/ml) 4.66±0.99 4.71±0.81 0.348 4.76±1.03 4.62±0.92 0.609 
fT4 (pmol/l) 17.15±3.47 17.81±3.63 0.354 16.78±2.68 17.65±3.71 0.222 
Blood Met (%) 20.99±8.07 22.31±5.11 0.143 21.43±7.36 21.27±7.56 0.811 
Met SAT (%) 11.95±5.86 16.34±6.54 0.011 13.56±7.38 12.69±5.83 0.784 
Met VAT (%) 17.04±5.61 19.69±6.10 0.038 18.20±4.41 17.46±6.18 0.401 
SAT HIF3A mRNA 21.08±72.62 7.43±40.53 0.209 11.58±49.82 22.60±76.47 0.660 
VAT HIF3A mRNA 23.92±106.19 10.45±50.03 0.073 16.80±82.25 24.09±106.69 0.729 
Leucoytes/nl 8.21±2.88 8.08±2.50 0.743 8.42±3.22 8.00±2.48 0.155 
Erythrocytes 
(Mio/µl) 
4.79±1.05 4.62±0.50 0.230 4.65±0.59 4.82±1.16 0.237 
Thrombocytes x109/l 257.94±82.94 291.52±101.69 0.089 261.59±75.91 263.98±93.83 0.762 
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Supplementary table 2. Due to the low minor allele frequency (MAF) of the studied polymorphisms, subjects 
homozygous for the minor alleles (n=3 for rs8102595, n=16 for rs3826795) were combined with heterozygous 
groups (i.e. dominant mode of inheritance was used for statistical analyses). p-value adjusted for age, gender 
and BMI and diabetes status; BMI – Body Mass Index, WHR – waist-to-hip ratio, SAT – subcutaneous adipose 
tissue, CRP –  C-reactive protein, IL-6 – Interleukin 6, HbA1c – glycohemoglobin, oGTT – oral glucose 
tolerance test, FPG – fasting plasma glucose, FPI – fasting plasma insulin, GIR – glucose infusion rate during 
the steady state of an euglycemic hyperinsulinemic clamp,  HDL-C – high density lipoprotein cholesterol, 
LDL-C – low density lipoprotein cholesterol , FFA – free fatty acids, TG – triglycerides, ALAT – alanine 
aminotransferase, ASAT - aspartate aminotransferase, gGT - gamma-glutamyl transferase, TSH – thyroid-
stimulation hormone, fT3 – free triiodothyronine, fT4 – free tetraiodothyronine, Met Blood (%) / Met Sc (%) 
/ Met Visc (%) - methylation of cg22891070 in HIF3A in blood / SAT / VAT, HIF3A mRNA – mRNA 
expression of HIF3A in subcutaneous/visceral adipose tissue. 
 
 
Supplementary Figure. Fat depot-related HIF3A mRNA expression pattern is distinct 
in individuals with either normal glucose tolerance (NGT; SAT, n=316; VAT, n=242) 
or type 2 diabetes (T2D; SAT, n=318; VAT, n=245) 
 
Supplementary Figure. NGT- normal glucose tolerance; SAT – subcutaneous adipose tissue; VAT – visceral 
adipose tissue, T2D – type 2 diabetes 
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